DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
SF1126 is an investigational drug.
There have been 4 clinical trials for SF1126. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Neuroblastoma, Carcinoma, Hepatocellular, and Carcinoma. The leading clinical trial sponsors are SignalRX Pharmaceuticals, Inc., University of California, San Diego, and Ezra Cohen.
There are eleven US patents protecting this investigational drug and forty-one international patents.
Recent Clinical Trials for SF1126
|A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma||University of California, San Diego||Phase 1|
|A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma||SignalRX Pharmaceuticals, Inc.||Phase 1|
|SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes||SignalRX Pharmaceuticals, Inc.||Phase 2|
Top disease conditions for SF1126
Top clinical trial sponsors for SF1126
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SF1126||Start Trial||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||Start Trial|
|SF1126||Start Trial||Benzothiophene-based selective estrogen receptor downregulators||The Board of Trustees of the University of Illinois (Urbana, IL)||Start Trial|
|SF1126||Start Trial||Benzothiophene estrogen receptor modulators||G1 Therapeutics, Inc. (Research Park Triangle, NC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|